The market has been flat this year with tech struggling to keep momentum. Investors seem to be rotating into biotech which is up 30% over the last year. Bank of America put out a note on two stocks they like in the sector. **Inhibikase Therapeutics (IKT)** They focus on pulmonary arterial hypertension. Their lead drug is an oral form of imatinib. The main update is they got cleared by the FDA to bypass Phase 2b and go directly to a pivotal Phase 3 trial. They also raised $100 million in November. BofA has a $6 price target which implies about 240% upside. **Wave Life Sciences (WVE)** They work on RNA therapies. Their obesity candidate showed fat reduction with lean mass preservation in Phase 1 trials. They are planning more studies this year. BofA sees potential here with a $38 price target.